T. Rowe Price Associates Reports 5.1% Stake in Crinetics Pharmaceuticals

T. Rowe Price Associates, Inc. filed a Schedule 13G/A on May 15, 2026, disclosing a 5.1% stake in Crinetics Pharmaceuticals, Inc. (CRNX). As of the event date on March 31, 2026, the investment firm reported beneficial ownership of 5,355,011 shares of common stock. This filing represents an increase from a previously reported 0.0% position, marking a significant new holding for the firm. The filing indicates that T. Rowe Price has sole voting power over 5,352,428 shares and sole dispositive power over the full 5,355,011 shares. The securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. T. Rowe Price, a Maryland-based investment adviser, expressly denies beneficial ownership of these securities beyond its role as an investment manager. The total value of the holding is estimated at approximately $196.9 million based on the reported share count.